drugset
Drugs / SAB-185
last change Jun 2023 re-read 2 minutes ago

SAB-185

Protein / enzyme biologic

Developed for
COVID-19
Investigated by
SAb Biotherapeutics, Inc. · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections · AstraZeneca · Biomedical Advanced Research and Development Authority · Brii Biosciences Limited · Bristol-Myers Squibb
+7 more · Department of Health and Human Services · Eli Lilly and Company · JPEO, Chemical, Biological, Radiological, and Nuclear Defense (CBRND) Enabling Biotechnologies (EB) · Joint Program Executive Office (JPEO) Chemical, Biological, Radiological, and Nuclear Defense (CBRND) Enabling Biotechnologies (EB) · National Institute of Allergy and Infectious Diseases (NIAID) · Sagent Pharmaceuticals Inc. · Synairgen Research Ltd.

Trials 3 · a red edge is where a trial was stopped

today NCT04469179 · Ph 1 NCT04518410 · Ph 2/3 NCT04468958 · Ph 1
202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT04469179 Aug 2020 → Feb 2021 COVID-19 SAb Biotherapeutics, Inc. Unknown No outcome recorded
Phase 1 NCT04468958 Jul → Dec 2020 COVID-19 SAb Biotherapeutics, Inc. Completed No outcome recorded
Phase 2/31 trial
Phase 2/3 NCT04518410 Aug 2020 → Apr 2022 COVID-19 National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as SAB-185 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04468958 ↗
2

NCT04469179 ↗

NCT04518410 ↗
Modality Protein / enzyme biologic “purified human immunoglobulin G (hIgG)” NCT04468958 ↗
Route Intravenous “administered intravenously” NCT04468958 ↗